DIADIA0.43%
SPYSPY0.07%
QQQQQQ0.55%
Trending
Top trending tickerAPLDAPLD0.40%
CAPRCAPR64.49%
NVDANVDA5.26%
ETHETH2.90%
XRPXRP4.05%
AMKRAMKR12.25%
VCXVCX31.05%
MPLTMPLT72.92%
CLSCLS13.01%
DOTDOT7.83%
Top trending tickerAPLDAPLD0.40%
CAPRCAPR64.49%
NVDANVDA5.26%
ETHETH2.90%
XRPXRP4.05%
AMKRAMKR12.25%
VCXVCX31.05%
MPLTMPLT72.92%
CLSCLS13.01%
DOTDOT7.83%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolCAPRnews
Exchange: NASDAQ·Updated 07:59 PM EDT
CAPR logo

CAPRCapricor Therapeutics Inc

$7.00
$12.71
(64.49%)
Today
Closed $7.00
$0.095
(1.36%)
After Hours
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ News·CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’
EarningsAug 11
Mkt Cap$1.14B
Vol30M
News
all
press releases
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC...
Business Wire
More News
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’
The documents released by the FDA on Monday, ahead of an advisory committee meeting to review Capricor’s application for Deramiocel, have raised a divide among Wall Street experts over what to expect.
Stocktwits
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.read more...
Benzinga
QUICK SPARK: Capricor Stock Dives 'Complete Fraud' Says Pharma Bro Martin Shkreli
Martin Shkreli accuses Capricor Therapeutics of fraud and predicts legal action against its CEO and consultant over patient data.read more...
Benzinga
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.
Stocktwits
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
Capricor Therapeutics fell over 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.read more...
Benzinga
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.
Stocktwits
CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel — Retail Deems It A ‘Binary Event’
An FDA advisory committee will review Capricor’s application for Deramiocel on July 29.
Stocktwits
CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity'
The Food and Drug Administration’s Advisory Committee is scheduled to meet on July 29 to review Capricor’s Biologics License Application for Deramiocel.
Stocktwits
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review
Capricor is working toward a potential FDA decision by Aug. 22, making the next two months a key regulatory stretch for CAPR investors.
Stocktwits
<
1
2
>

Advertisement|Remove ads.

Advertisement|Remove ads.